Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 271

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia

Open access
Frey, Noelle V., Shaw, Pamela A., Hexner, Elizabeth O., Pequignot, Edward, Gill, Saar, Luger, Selina M., Mangan, James K., Loren, Alison W., Perl, Alexander E., Maude, Shannon L., Grupp, Stephan A., Shah, Nirav N., Gilmore, Joan, Lacey, Simon F., Melenhorst, Jos J., Levine, Bruce L., June, Carl H., Porter, David L.·2020·Journal of Clinical Oncology

Abstract

PURPOSE: The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel (CTL019) has an 81% response rate in children with relapsed or chemotherapy refractory (r/r) B-cell acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is a life-threatening treatment-related toxicity that limits the full therapeutic potential in adults. We report outcomes for adults with r/r ALL treated with an optimized CTL019 dosing and CRS management strategy. METHODS: Adults with r/r B-cell ALL received CTL019 in 1 of 2 trials. Patients received lymphodepletion followed by CTL019 as either a one-time infusion or fractionated infusions split over 3 days (day 1, 10%; day 2, 30%; day 3, 60%), which allowed for day 2 and day 3 doses to be held for early CRS. Total planned CTL019 dose varied with adaptive protocol modifications in response to efficacy and CRS toxicity. RESULTS: Thirty-five adults with r/r ALL received CTL019 in 1 of 3 dosing cohorts. The low-dose cohort (n = 9) received single or fractionated dosing and had manageable toxicity with a 33% complete remission (CR) rate. In the high-dose single infusion cohort, 3 of 6 patients with refractory CRS concurrent with culture-positive sepsis died, and 3 achieved CR. The 20 patients in the high-dose fractionated (HDF) cohort had a 90% CR rate and manageable CRS. The HDF cohort had the highest survival, with a 2-year overall survival of 73% (95% CI, 46% to 88%) and event-free survival of 49.5% (95% CI, 21% to 73%). CONCLUSION: Fractionated dosing of CTL019 with intrapatient dose modification optimizes safety without compromising efficacy in adults with r/r ALL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.01892

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 271

Metadata

Authors
Frey, N. V., Shaw, P. A., Hexner, E. O., Pequignot, E., Gill, S., Luger, S. M., Mangan, J. K., Loren, A. W., Perl, A. E., Maude, S. L., Grupp, S. A., Shah, N. N., Gilmore, J., Lacey, S. F., Melenhorst, J. J., Levine, B. L., June, C. H., & Porter, D. L.
Venue
Journal of Clinical Oncology
Published
2020-02-10
Volume
38
Issue
5
Pages
415-422
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2992389962
Cited by
271
References
8
FWCI
11.25
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. https://app.cochat.ai/papers/10.1200/jco.19.01892
The paper
Frey, N. V., Shaw, P. A., Hexner, E. O., Pequignot, E., Gill, S., Luger, S. M., Mangan, J. K., Loren, A. W., Perl, A. E., Maude, S. L., Grupp, S. A., Shah, N. N., Gilmore, J., Lacey, S. F., Melenhorst, J. J., Levine, B. L., June, C. H., & Porter, D. L. (2020). Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.01892

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.